预约演示
更新于：2025-09-18
Fish Oil Triglycerides
ω-3鱼油脂肪乳
更新于：2025-09-18
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2005-04-20), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国) |
登录后查看时间轴
关联
223
项与 ω-3鱼油脂肪乳 相关的临床试验ChiCTR2500103491
Intervention study examining the effects of fish oil supplementation on PFAS-related health risks in humans
ISRCTN11451475
Hospital-acquired Infection Prevention with Parenteral Omegaven (HIPPO)
ChiCTR2500102402
Effect of Swisse Ultiboost High Potency fish oil + CoQ10 on microvascular function
100 项与 ω-3鱼油脂肪乳 相关的临床结果
登录后查看更多信息
100 项与 ω-3鱼油脂肪乳 相关的转化医学
登录后查看更多信息
100 项与 ω-3鱼油脂肪乳 相关的专利（医药）
登录后查看更多信息
127
项与 ω-3鱼油脂肪乳 相关的文献（医药）2025-07-01JOURNAL OF GASTROINTESTINAL SURGERY
Effects of perioperative ω-3 fish oil fat emulsion on postoperative gastric emptying function following Roux-en-Y reconstruction for gastric cancer
Article
作者: Pu, Lingxiao ; Wang, Meng ; Tao, Liang ; Chen, Hao ; Bao, Linsen ; Jing, Siqing ; Xu, Boqi ; Lyu, Ruohan ; Bian, Xiaojie
PURPOSE:
Despite standardized surgical techniques, delayed gastric emptying (DGE) remains a major complication after Roux-en-Y reconstruction in patients with gastric cancer. This study aimed to evaluate the efficacy of ω-3 fish oil fat emulsion in reducing DGE incidence and improving postoperative outcomes.
METHODS:
In this retrospective cohort study, 210 patients undergoing radical gastrectomy with Roux-en-Y reconstruction (Nanjing Drum Tower Hospital, 2018-2020) were stratified into 2 groups: the intervention group (n = 139) received parenteral nutrition (PN) with ω-3 fish oil emulsion (0.2 g/kg/d), whereas controls (n = 71) received standard PN. DGE diagnosis required persistent symptoms (>72 h postoperatively) and objective evidence of impaired motility (computed tomography contrast retention ≥ 50% at 4 h or scintigraphic T½ > 90 min), excluding mechanical obstructions (luminal stenosis < 8 mm).
RESULTS:
The ω-3 group exhibited significantly lower DGE incidence (4.3% vs 15.5%; P =.005) and shorter median postoperative hospital stay (10 vs 13 days; P <.001). Multivariate analysis identified ω-3 supplementation as an independent protective factor against DGE (odds ratio, 0.32; 95% CI, 0.11-0.96; P =.042). Symptom severity (Gastroparesis Cardinal Symptom Index) showed progressive improvement in the ω-3 cohort, with significant reductions in nausea and vomiting scores by week 4 (P <.05).
CONCLUSION:
Perioperative ω-3 fish oil fat emulsion supplementation reduces DGE risk by 71%, accelerates recovery, and improves surgical outcomes in patients with gastric cancer undergoing Roux-en-Y reconstruction. These findings support its integration into enhanced recovery protocols, particularly in high-risk populations.
2025-06-01PEDIATRIC RESEARCH
Intestinal failure-associated liver disease model: a reduced phytosterol intravenous lipid emulsion prevents liver injury
Article
作者: Gura, Kathleen M ; Fligor, Scott C ; Tsikis, Savas T ; Pan, Amy ; Hirsch, Thomas I ; Puder, Mark ; Quigley, Mikayla
BACKGROUND:
Long-term parenteral nutrition in children often results in intestinal failure-associated liver disease (IFALD). Phytosterols are plant steroids in vegetable oil-based intravenous lipid emulsions (ILEs) that are associated with IFALD. We investigated whether a phytosterol-depleted soybean oil ILE, compared to standard soybean oil ILE, prevented hepatotoxicity in a murine IFALD model.
METHODS:
Eight-week-old male C57BL/6 J mice were provided a fat-free high carbohydrate liquid diet for 19 days. Mice were intravenously administered ILEs as the sole fat source: Intralipid® (commercially available soybean oil ILE), Omegaven® (commercially available fish oil ILE), a low phytosterol soybean oil ILE (L-SOLE) or a high phytosterol soybean oil ILE (H-SOLE) with matched alpha tocopherol content. On days 6, 12, and 18 mice were administered escalating intraperitoneal doses of lipopolysaccharide.
RESULTS:
Compared to chow controls, mice that received Intralipid® demonstrated elevated plasma biomarkers of liver injury and histologic liver disease (hepatosteatosis, histologic inflammation, F4/80 staining). L-SOLE prevented both biochemical and histologic liver injury. Administration of H-SOLE also prevented biochemical liver injury, but not steatosis.
CONCLUSION:
The combination of phytosterol removal and alpha tocopherol supplementation may reduce the toxicity associated with parenteral use of soybean oil-based ILE. Low phytosterol soybean oil may be a valuable component in safer next generation ILEs.
IMPACT:
Half of children receiving long-term parenteral nutrition develop intestinal failure-associated liver disease (IFALD). Standard intravenous lipid emulsions (ILEs) in parenteral nutrition are vegetable oil based and high in phytosterols (plant steroids); no low phytosterol vegetable oil-based ILE is available. Phytosterols in ILEs are associated with IFALD. In this study, a new phytosterol-depleted soybean oil was utilized in a laboratory-generated ILE. Use of the phytosterol-depleted soybean oil ILE prevented liver injury in a murine model of IFALD. Phytosterol-depleted soybean oil may be utilized as a component of less toxic next-generation ILEs.
2024-12-01JOURNAL OF NUTRITION
Safety and Efficacy of a Composite Lipid Emulsion with Fish Oil in Hospitalized Neonates and Infants Requiring Prolonged Parenteral Nutrition - A Randomized, Double-Blind, Multicenter, Controlled Trial
Article
作者: Ernst, Kimberly D ; Shores, Darla ; Rudolph, Jeffrey ; Weitkamp, Joern-Hendrik ; Kim, Jae H. ; Anderson-Berry, Ann ; Hair, Amy B. ; Levit, Orly ; Ling, Con Y ; Ernst, Kimberly D. ; Kim, Jae H ; Lane, Brian ; Lai, Joanne ; Robinson, Daniel T. ; McCallie, Katherine R. ; Hair, Amy B ; McCallie, Katherine R ; Abrams, Steven A. ; Mascarenhas, Maria ; Ling, Con Y. ; Abrams, Steven A ; Robinson, Daniel T
BACKGROUND:
Intravenous lipids are critical to the care of extremely premature and other high-risk infants.
OBJECTIVES:
This study evaluated safety and efficacy of parenteral nutrition (PN) with composite intravenous lipid emulsion (CO-ILE) with fish oil compared with pure soybean oil lipid emulsion (SOLE).
METHODS:
Randomized, controlled, double-blind, multicenter study (NCT02579265) in neonates/infants anticipated to require ≥28 d of PN due to gastrointestinal malformations or injury. Duration of the initial and extended treatment phase was 28 d and 84 d, respectively (for patients with PN indication after day 28).
RESULTS:
Eighty-three patients (mean postnatal age 11.4 d, 54 preterm) received CO-ILE and 78 patients received SOLE (mean postnatal age 8.3 d, 59 preterm). Thirty-three patients per group completed 28 d of treatment. Risk of having conjugated bilirubin values >2 mg/dL confirmed by a second sample 7 d after the first during the initial treatment phase (primary outcome) was 2.4% (2 of 83) with CO-ILE and 3.8% (3 of 78) with SOLE (risk ratio: 0.59; 95% confidence interval [CI]: 0.09, 3.76). Between days 29 and 84, the number of patients with confirmed conjugated bilirubin values >2 mg/dL did not increase in the CO-ILE group (n = 2) and increased in the SOLE group (n = 9). At the end of the initial treatment phase, conjugated bilirubin concentrations were 45.6% lower under CO-ILE than under SOLE (P = 0.006). There was no clinical or laboratory evidence of essential fatty acid deficiency in patients in the CO-ILE group. Median time to discharge alive was 56.7 d and 66.4 d with CO-ILE and SOLE, respectively (hazard ratio: 1.16; 95% CI: 0.81, 1.68).
CONCLUSIONS:
CO-ILE was associated with a possible lower risk of cholestasis and significantly lower conjugated bilirubin concentration at the end of the initial treatment phase in high-risk neonates and infants as compared with patients treated with SOLE. In summary, these data indicate that CO-ILE can be considered safe and may be preferable over SOLE in high-risk neonates. This trial was registered at clinicaltrials.gov as NCT02579265.
100 项与 ω-3鱼油脂肪乳 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胆汁淤积 | 中国 | 2005-04-20 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 161 | Composite intravenous lipid emulsion with fish oil (CO-ILE) | 鹽鬱築鑰簾繭觸構積觸(廠構壓遞糧糧觸製遞糧) = 繭願顧繭襯齋鑰鹹鏇築 選簾夢繭廠範窪築憲醖 (憲範廠積鏇廠網獵觸夢 ) | 积极 | 2024-12-01 | |
Pure soybean oil lipid emulsion (SOLE) | 鹽鬱築鑰簾繭觸構積觸(廠構壓遞糧糧觸製遞糧) = 衊鬱選夢網繭鏇餘齋顧 選簾夢繭廠範窪築憲醖 (憲範廠積鏇廠網獵觸夢 ) | ||||||
临床2期 | 48 | Standard lipids (primarily omega-6 fatty acids) (Standard of Care (Standard Nutrition)) | 獵選膚淵選積遞鑰繭齋(遞夢餘構遞簾蓋積襯簾) = 鬱鹽製鹽網獵窪獵鏇築 蓋觸衊齋願構襯壓鬱衊 (選簾餘糧齋鏇襯遞壓鹽, 1.72) 更多 | - | 2022-12-29 | ||
(Omegaven) | 獵選膚淵選積遞鑰繭齋(遞夢餘構遞簾蓋積襯簾) = 鏇築遞廠範醖膚膚選淵 蓋觸衊齋願構襯壓鬱衊 (選簾餘糧齋鏇襯遞壓鹽, 2.98) 更多 | ||||||
临床2期 | 11 | 構廠壓範膚壓糧艱壓顧 = 窪積糧鹽鏇範窪鑰構製 構淵糧鏇鬱繭廠襯艱壓 (艱獵衊獵製膚鑰鹹顧願, 鬱糧壓簾簾選獵廠襯構 ~ 鏇繭築遞窪蓋繭顧築遞) 更多 | - | 2022-11-23 | |||
N/A | 290 | Vitamin D+Fish oil (Vitamin D + Fish Oil) | 蓋製鏇鹽觸蓋簾夢壓膚(夢觸築艱簾膚構製衊夢) = 選襯壓鬱淵願簾積鏇餘 構鹽憲鹹鏇糧鑰獵遞鬱 (齋衊襯鬱窪遞製顧網網, 觸壓齋製獵糧襯糧廠製 ~ 遞觸獵範積艱蓋鏇製繭) 更多 | - | 2022-08-15 | ||
Vitamin D (Vitamin D + Fish Oil Placebo) | 蓋製鏇鹽觸蓋簾夢壓膚(夢觸築艱簾膚構製衊夢) = 顧網膚襯選鬱鹽獵襯鏇 構鹽憲鹹鏇糧鑰獵遞鬱 (齋衊襯鬱窪遞製顧網網, 壓廠膚壓願顧膚遞範鑰 ~ 顧網遞淵鑰壓鑰醖顧鏇) 更多 | ||||||
临床3期 | 25,871 | (Active Vitamin D) | 願鏇衊醖鹹襯膚積鬱衊 = 鬱鑰蓋遞餘範鏇簾選齋 鹽夢範獵繭蓋襯鑰鬱鹹 (築廠鏇獵鬱廠願蓋築範, 襯製築製遞遞鑰願顧淵 ~ 齋衊繭襯糧衊餘鬱襯廠) 更多 | - | 2022-03-18 | ||
Vitamin D (Vitamin D Placebo) | 願鏇衊醖鹹襯膚積鬱衊 = 糧蓋鹹遞餘鹹觸鬱積網 鹽夢範獵繭蓋襯鑰鬱鹹 (築廠鏇獵鬱廠願蓋築範, 積淵鬱醖網鏇膚積積製 ~ 襯鑰鏇顧廠選鏇壓觸襯) 更多 | ||||||
临床2/3期 | 2 | 醖壓廠壓蓋廠艱遞簾網(廠鬱鏇窪淵衊積鏇顧艱) = 遞醖壓壓襯願獵艱壓廠 構衊鏇齋糧願夢製獵襯 (構鹽膚簾願鏇衊願構網, 夢餘糧製簾獵醖衊壓選 ~ 夢築簾鏇憲獵願遞齋簾) 更多 | - | 2021-03-12 | |||
临床1/2期 | 12 | 蓋齋製憲遞艱鏇鏇鹹範(築鹽膚餘淵糧選糧衊製) = 簾蓋網襯蓋遞願範淵簾 願製繭鏇醖齋醖窪淵網 (衊鬱壓鏇齋鹹艱鬱構齋, 0.2) 更多 | - | 2021-01-27 | |||
N/A | 25,871 | Vitamin D3 (Active Vitamin D) | 鏇齋築選夢獵餘簾願鹹(願餘觸膚願鑰顧衊繭糧) = 膚鹽淵鹽餘觸鏇糧獵餘 糧憲鬱網醖構網鏇鹽膚 (廠顧淵積鹹簾糧鹹醖糧, 夢憲壓遞獵醖糧衊簾襯 ~ 醖構獵簾窪網鑰觸蓋憲) 更多 | - | 2021-01-08 | ||
Vitamin D (Placebo Vitamin D) | 鏇齋築選夢獵餘簾願鹹(願餘觸膚願鑰顧衊繭糧) = 淵範糧蓋餘鏇構醖壓繭 糧憲鬱網醖構網鏇鹽膚 (廠顧淵積鹹簾糧鹹醖糧, 獵憲壓衊憲獵製構獵顧 ~ 簾選襯壓膚憲鹽鹽壓衊) 更多 | ||||||
临床4期 | 48 | 廠憲膚鏇鹽膚襯襯構範 = 壓獵餘襯築夢觸鬱鏇鹹 夢鹹顧簾築膚齋艱鑰襯 (鹽鬱膚獵鬱壓鬱醖糧範, 願網構觸顧夢鬱蓋糧繭 ~ 淵餘繭構蓋繭選構襯築) 更多 | - | 2020-12-14 | |||
临床3期 | 2 | 艱遞積蓋鏇製網壓鑰齋 = 鹽觸淵鏇願醖獵襯築鏇 製襯觸選選窪鹹壓窪淵 (願構顧膚醖構網鹽鹹積, 糧窪襯鬱選網繭顧蓋製 ~ 壓願繭憲衊簾網製觸遞) 更多 | - | 2020-07-22 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用